Intron Bio Technology Inc. is engaged in developing of bacterial bio-drugs for the treatment of infectious diseases. The company offers products such as N-Rephasin antibiotics, such as SAL200, EFL200, CDL200, TMA015, NFA014, and various other candidates. Intron Bio Technology Inc. products target VRSA and MRSA, and typical gram positive bacteria, as well as other antibiotic resistant bacteria, including VRE, MRPA, MRAB, CRE among others. The company also develops drugs targeting functional moiety program, including axakacin, pterostilbene, methylated flavonoid, etc. for use in silver and brain industries. Intron Bio Technology Inc. was incorporated in 1999 and is based in Seongnam, South Korea.
Headquarters
701~ 704 5Th Joongang Induspia, 138-6 Sangdaewon, Jongwon, Seongnam
Seongnam; Gyeonggi;
Postal Code: 462-120
Contact Details: Purchase the Intron Bio Technology Inc. report to view the information.
Website: http://www.intron.co.kr
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service